Novozymes A/S purchases B shares from Novo A/S
Novozymes A/S purchases B shares worth DKK 244 million from Novo A/S as part of the ongoing share buy-back programme.
Novo A/S has hereby reduced its ownership of Novozymes A/S to its target level, which is the level of Novo A/S' ownership of Novozymes A/S following the demerger from Novo Nordisk A/S in the year 2000.
Novo A/S' shareholding in Novozymes A/S prior to the sale of B shares was 10.748.720 A shares (nominal DKK 10) and 7.764.280 B shares (nominal DKK 10), corresponding to 26.6% of capital and 69.3% of votes. The current transaction reduces Novo A/S' ownership of Novozymes A/S to 25.5% of capital and 68.8% of votes.
Henrik Gürtler, CEO of Novo A/S, said: "Novo A/S has now adjusted its shareholding in Novozymes A/S so that it is again 25.5% of the capital, as was the case prior to the reduction in share capital implemented recently. Novo A/S remains a long-term and committed major shareholder in Novozymes A/S."
As of August 29, 2005, Novozymes A/S has bought back B shares amounting to around DKK 737 million, as part of the DKK 850 million share buy-back programme for 2005 and as part of the ongoing share buy-back programme of DKK 2.5 billion. Novozymes A/S now owns 4,784,764 of its own B shares of DKK 10, corresponding to a total nominal value of DKK 47,847,640 or 6.88% of the total share capital.
At the Annual Meeting of Shareholders on March 16, 2005, it was decided to reduce the nominal share capital with 3 million shares. Pursuant to the Stock Exchange announcement on July 4, 2005 the capital reduction has now been finally registered. It is the policy of Novozymes A/S to reduce its share capital by the number of shares bought back.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
